Table 1.
Patient characteristics.
| Patient Characteristic † | Mean (SD), Number (%) |
Available Data/Total Number |
|---|---|---|
| Age | 52/52 | |
| Age (years) | 56.4 (9.2) | |
| Range (years) | 37–76 | |
| Sex | 52/52 | |
| female | 30 (58%) | |
| male | 22 (42%) | |
| Body weight | 51/52 | |
| BMI (kg/m2) | 27.3 (5.3) | |
| Current smoker | 11 (21%) | 52/52 |
| Tumor Stage ‡ | 49/52 | |
| Stage I | 30 (61.2%) | |
| Stage II | 5 (10.2%) | |
| Stage III | 14 (28.6%) | |
| Stage IV | 0 (0%) | |
| Range | IA—IIIA | |
| Histology | 52/52 | |
| NSCLC | 44 (84.6%) | |
| Adenocarcinoma | 33 (63.5%) | |
| Squamous-cell carcinoma | 5 (9.6%) | |
| Adeno-squamous carcinoma | 1 (1.9%) | |
| NSCLC-NOS | 5 (9.6%) | |
| Neuro-endocrine tumor | 8 (15.4%) | |
| SCLC | 1 (1.9%) | |
| LC-NEC III | 2 (3.8%) | |
| Carcinoid tumor | 5 (9.6%) | |
| Prior oncologic therapy | 44/52 52/52 |
|
| Chemotherapy | 24 (54.5%) | |
| Surgery | 52 (100%) |
BMI, body mass index; NSCLC, non-small-cell lung cancer; NSCLC-NOS, non-small-cell lung cancer not otherwise specified; SCLC, small-cell lung cancer; LC-NEC III, large-cell neuroendocrine carcinoma grade III; † percentage may not be 100 because of rounding; ‡ staging per UICC Version 8.